Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
62.3M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
18.3M
-
Shares change
-
-506K
-
Total reported value, excl. options
-
$110M
-
Value change
-
-$3.12M
-
Number of buys
-
19
-
Number of sells
-
-8
-
Price
-
$6.02
Significant Holders of Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) as of Q4 2021
36 filings reported holding ELEV - Elevation Oncology, Inc. - Common stock, par value $0.0001 per share as of Q4 2021.
Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.3M shares
of 62.3M outstanding shares and own 29.36% of the company stock.
Largest 10 shareholders include Aisling Capital Management LP (2.83M shares), venBio Partners LLC (2.61M shares), Qiming U.S. Ventures Management, LLC (2.37M shares), Cormorant Asset Management, LP (1.98M shares), DRIEHAUS CAPITAL MANAGEMENT LLC (1.98M shares), BVF INC/IL (1.61M shares), JANUS HENDERSON GROUP PLC (1.14M shares), Samsara BioCapital, LLC (932K shares), BOXER CAPITAL, LLC (873K shares), and TCG Crossover Management, LLC (555K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.